Fulcrum Therapeutics Q1 net loss $18.9M, CFO retiring, CAMP4 license terminated, pociredir trial planned H2 2026

Fulcrum Therapeutics, Inc.

2026-Q1 EPS reported -$0.25

CFO Alan Musso retiring; will stay until successor named then consultant through Feb 2027.
Terminated CAMP4 license for Diamond-Blackfan anemia program; no further milestone/royalty payments.
Q1 net loss $18.9M ($17.7M Q1 2025); cash $333.3M, runway into 2029.
Positive pociredir Phase 1b data: HbF induction, hemolysis/anemia improvements; registration-enabling trial H2 2026.
Board appointed Josh Lehrer M.D., independent, receives option for 64,000 shares at $8.08.

item 1.02 item 2.02 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Fulcrum Therapeutics, Inc. reported first quarter of 2026 results: net income $18.9 million.

Period: first quarter of 2026
Net income: $18.9 million
Result: reported results

Exact text from the filing

higher employee compensation costs, including $0.3 million of increased stock-based compensation expense, as well as higher professional services costs. • Net Loss: Net loss was $18.9 million for the three months ended March 31, 2026, compared to a net loss of $17.7 million for the three months ended March 31, 2025. Cash Runway Guidance Based on its current operating

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Fulcrum Therapeutics, Inc. terminated CAMP4 License with CAMP4 Therapeutics Corp. (effective 2026-04-23).

Action: termination
Agreement: license
Counterparty: CAMP4 Therapeutics Corp.
Effective: 2026-04-23

Exact text from the filing

On April 23, 2026, Fulcrum Therapeutics, Inc., or Fulcrum, provided written notice to CAMP4 Therapeutics Corp., or CAMP4, of termination of the License Agreement dated July 5, 2023, between Fulcrum and CAMP4, or the CAMP4 License, which termination will be effective in accordance with the terms of such agreement.

View on SEC.gov

Browse all earnings releases →

Fulcrum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-178806

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.